Finland· FI-REL-REL4098
Buscopan compositum vet.
A butyyliskopolamiini ja analgeetti product containing hyoscine butylbromide + metamizole sodium, registered in Finland by Boehringer Ingelheim Vetmedica GmbH. The same ATC class is registered in 2 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Hyoscine butylbromide + metamizole sodium is registered in 2 of 19 countries.
Countries holding a registration under ATC QA03DB04 (butyyliskopolamiini ja analgeetti), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 1 of them publish a price we can compare per daily dose
Hyoscine butylbromide + metamizole sodium · ATC QA03DB04
2 / 19 countries
- Denmark
- Finlandprice
The record
At a glance
Fimea (Finland)- Active substance
- Hyoscine butylbromide + Metamizole sodium
- Manufacturer
- Boehringer Ingelheim Vetmedica GmbH
- Country
- Finland (FI)
- ATC code
- QA03DB04
- ATC class
- Butyyliskopolamiini ja analgeetti
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under QA03DB04
Butyyliskopolamiini ja analgeetti, as other registers publish it.
- FinlandSpasmium vet.VetViva Richter GmbH
- DenmarkSpasmium Vet.VetViva Richter GmbH
- FinlandSympagesicDechra Regulatory B.V.
- DenmarkSympagesicDechra Regulatory B.V.
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Spain · Buscopresc Compositum
- Poland · Scopolan Compositum
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ee22c8f3-14b6-45e2-b57f-3a4dc628d36d GET /v1/drugs/ee22c8f3-14b6-45e2-b57f-3a4dc628d36d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "injektioneste, liuos",
"route": "Laskimoon",
"ddd_unit": null,
"strength": null,
"atc_label": "Butyyliskopolamiini ja analgeetti",
"ma_number": "12024",
"auth_status": "Myyntilupa peruuntunut",
"eu_ma_number": null,
"fimea_rel_id": "REL4098",
"authorised_at": "1997-08-07"
}See everything about hyoscine butylbromide + metamizole sodium.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.